: Curis’s stock rises as analysts see ‘the next Pharmacyclics’

Shares of Curis rose premarket Friday as analysts see biotech company as potential take-out target

Previous post Economic Report: U.S. housing starts rise ‘unexpectedly’ for the second straight month
Next post Futures Movers: Oil prices recover but still on track to see biggest 2-week drop since March